Thursday 24th July 2025, 17:00 - 18:00
Join the Diabetes Technology Network UK (DTN-UK) for a discussion of the current state of hybrid closed loop (HCL) rollout and any issues arising from this.
Together we will explore:
Please note this draft programme is subject to change
The use of HCL may enable provision of different CGM options. We agree that, provided accuracy standards are met, cost-effectiveness needs to be considered, and therefore encourage choice based on clinical need, with selection of the lowest cost device that meets an individual’s specific requirements. It is sensible that the lowest cost option should be the default choice, but where this does not meet an individual’s requirements an alternative should be available.
Updated: 2024
The primary purpose of these guidelines is to provide practical recommendations on lipid management for diabetologists, nephrologists, general practitioners and other members of the multidisciplinary team involved in the care of adults with diabetic kidney disease (DKD)
The ABCD nationwide tirzepatide audit is now launched. ABCD members are invited to contribute to the audit.
As with all our audits, all contributors will be acknowledged in publications emanating from the audit and the biggest contributors will become co-authors.
You can also find out more about this and all the ABCD Audits within the Audits section of our website.
